NOBITAN
NOBITAN
Novel biofocused targeting of nucleoside analogues with cyclic RGD peptides as enhanced anticancer therapy
ABSTRACT
NOBITAN is aimed at the development of novel chemotherapeutic products exhibiting an enhanced safety and efficacy profile, through a selective targeting of inactive cytotoxic compounds toward tumor cells, and a smart release and local activation of the anticancer drug.
Project Budget: 967’000 €
Financial Framework: ERA-NET
Contract number: IUE/4066/2010
Start Date: 01/09/2011
End Date: 01/08/2013
Partners:
Contact Manager: I. Alfany
This project has received funding from the European Union’s Seventh Programme for research, technological development and demonstration and from ACCIÓ – Generalitat de Catalunya.